Is Kamada (KMDA) Outperforming Other Medical Stocks This Year?
Investors focused on the Medical space have likely heard of Kamada (KMDA), but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Kamada is a member of our Medical group, which includes 833 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. KMDA is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for KMDA's full-year earnings has moved 33.33% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, KMDA has moved about 17.60% on a year-to-date basis. In comparison, Medical companies have returned an average of 10.44%. This means that Kamada is performing better than its sector in terms of year-to-date returns.
Breaking things down more, KMDA is a member of the Medical - Biomedical and Genetics industry, which includes 344 individual companies and currently sits at #89 in the Zacks Industry Rank. On average, this group has gained an average of 13.14% so far this year, meaning that KMDA is performing better in terms of year-to-date returns.
Investors in the Medical sector will want to keep a close eye on KMDA as it attempts to continue its solid performance.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Kamada Ltd. (KMDA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
